New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
10:01 EDTSYRG, RBCN, FLY, ABBV, VRTX, TRLA, DLA, MLNX, PFE, VCLK, OPTR, FIO, GOOGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Delta Apparel (DLA) initiated with a Buy at Roth Capital... Fly Leasing (FLY) initiated with a Buy at Deutsche Bank... Google (GOOG) initiated with a Neutral at Sterne Agee... Optimer (OPTR) initiated with an Outperform at RW Baird... Trulia (TRLA) initiated with a Neutral at Goldman... ValueClick (VCLK) initiated with a Buy at Goldman... Vertex (VRTX) initiated with an Outperform at RW Baird... Rubicon (RBCN) coverage resumed with an Underweight at Piper Jaffray... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Pfizer (PFE) reinstated with a Neutral at Credit Suisse... AbbVie (ABBV) initiated with a Neutral at Credit Suisse... Fusion-io (FIO) initiated with a Neutral at Janney Capital... Mellanox (MLNX) initiated with a Buy at Janney Capital.
News For GOOG;DLA;FLY;OPTR;TRLA;RBCN;VCLK;VRTX;SYRG;PFE;ABBV;FIO;MLNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 9, 2014
07:44 EDTPFE, ABBVAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
06:14 EDTGOOGGoogle launches Street View in Dubai
Subscribe for More Information
06:00 EDTGOOGSalesforce.com names YouTube CEO Susan Wojcicki to board
Subscribe for More Information
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:40 EDTSYRGMany E&P target prices lowered at SunTrust
Subscribe for More Information
07:28 EDTMLNXFBN Securities to hold a bus tour
Subscribe for More Information
December 7, 2014
13:47 EDTGOOGGoogle could reach $634 in a year, Barron's says
Google shares look attractive at current levels and shares could reach $634.00 in a year, driven by stabilizing ad pricing, Barron's contends in a feature article. Reference Link
December 5, 2014
12:50 EDTGOOGOn The Fly: Midday Wrap
Subscribe for More Information
10:22 EDTPFEBristol-Myers call activity attributed to takeover speculation
Subscribe for More Information
10:20 EDTGOOGYahoo rises, Google falls after BofA changes ratings on both
Shares of Yahoo (YHOO) are rising and Google's (GOOG, GOOGL) stock is falling after Bank of America Merrill Lynch upgraded Yahoo and downgraded Google. WHAT'S NEW: Bank of America analyst Justin Post upgraded his rating on Yahoo to Buy from Neutral. Post said he had previously not expected to obtain information about Yahoo's strategy for avoiding taxes on the sale of its stake in Chinese e-commerce giant Alibaba (BABA) at least until well into 2015. However, Yahoo's CFO recently stated that the company continued to be optimistic that it would be able to cut its tax bill and added that the company would divulge its plans for doing so during its next earnings conference call. Yahoo's next earnings conference call is expected to take place by the end of next month, Post noted. He set a $62 price target on Yahoo shares. Meanwhile, Post downgraded Google to Neutral from Buy. The analyst thinks the company is facing several headwinds, including the maturity of its search business, a lack of products that can provide catalysts, and margin pressures as it invests in competitive businesses. As a result of these headwinds, Google's results are likely to be below expectations, Post believes. Meanwhile, the company is also facing increased regulatory risk, particularly in the EU, and increased competition from Facebook (FB) and other social networks. He trimmed his price target on Google to $580 from $600. PRICE ACTION: In early trading, Yahoo climbed 1% to $50.94, while Google class A shares declined 1.5% to $534.33.
10:05 EDTPFEBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
10:00 EDTGOOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:56 EDTPFERumor: Bristol-Myers strength attributed to takeover speculation
Subscribe for More Information
08:55 EDTGOOGYahoo seen overtaking Twitter in U.S. mobile ad market share, WSJ reports
Research firm eMarketer predicts Google (GOOG, GOOGL) and Facebook (FB) will account for about 35% and 17%, respectively, of the U.S. mobile ad market in 2015, but the firm also expects Yahoo (YHOO) will edge past Twitter (TWTR) in terms of mobile ad revenue, with projected market shares of 3.74% and 3.69%, respectively, reported The Wall Street Journal. Reference Link
08:14 EDTGOOGGoogle volatility low into being downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
07:38 EDTGOOGFollow-up: Google downgraded at BofA/Merrill
As previously reported, BofA/Merrill downgraded Google to Neutral from Buy. The firm lowered estimates slightly below the Street due to lack of product catalysts, search maturity, and margin pressure from investments. BofA/Merrill is also cautious on online advertising growth given increased regulatory risk in the EU, potential Facebook (FB) competition, share loss from social growth, and a strong Apple (AAPL) product cycle. Price target lowered to $580 from $600.
07:28 EDTGOOGGoogle downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information
06:15 EDTGOOGGoogle revamps incentive program for firms that sell productivity apps, services
Subscribe for More Information
06:03 EDTGOOGiOS mobile traffic shows iPhone 6 launch strong, says Piper Jaffray
Piper Jaffray says that according to Quantcast data, Apple's (AAPL) iOS mobile traffic share increased from 60.6% at iPhone 6 launch to 61.4% nine weeks after launch, while Google's (GOOG) Android decreased from 38.4% to 37.5% in the same period. Piper views the iOS mobile traffic share as further evidence that the iPhone 6 launch in the U.S. is off to a strong start. It keeps an Overweight rating on Apple shares with a $135 price target.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use